306 related articles for article (PubMed ID: 20198649)
1. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease.
Wolf E; Seppi K; Katzenschlager R; Hochschorner G; Ransmayr G; Schwingenschuh P; Ott E; Kloiber I; Haubenberger D; Auff E; Poewe W
Mov Disord; 2010 Jul; 25(10):1357-63. PubMed ID: 20198649
[TBL] [Abstract][Full Text] [Related]
2. [Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
Cersósimo MG; Scorticati MC; Micheli FE
Medicina (B Aires); 2000; 60(3):321-5. PubMed ID: 11050808
[TBL] [Abstract][Full Text] [Related]
3. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.
Ory-Magne F; Corvol JC; Azulay JP; Bonnet AM; Brefel-Courbon C; Damier P; Dellapina E; Destée A; Durif F; Galitzky M; Lebouvier T; Meissner W; Thalamas C; Tison F; Salis A; Sommet A; Viallet F; Vidailhet M; Rascol O;
Neurology; 2014 Jan; 82(4):300-7. PubMed ID: 24371304
[TBL] [Abstract][Full Text] [Related]
4. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
da Silva-Júnior FP; Braga-Neto P; Sueli Monte F; de Bruin VM
Parkinsonism Relat Disord; 2005 Nov; 11(7):449-52. PubMed ID: 16154788
[TBL] [Abstract][Full Text] [Related]
5. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
Stathis P; Konitsiotis S; Tagaris G; Peterson D;
Mov Disord; 2011 Feb; 26(2):264-70. PubMed ID: 21412833
[TBL] [Abstract][Full Text] [Related]
6. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.
Berg D; Godau J; Trenkwalder C; Eggert K; Csoti I; Storch A; Huber H; Morelli-Canelo M; Stamelou M; Ries V; Wolz M; Schneider C; Di Paolo T; Gasparini F; Hariry S; Vandemeulebroecke M; Abi-Saab W; Cooke K; Johns D; Gomez-Mancilla B
Mov Disord; 2011 Jun; 26(7):1243-50. PubMed ID: 21484867
[TBL] [Abstract][Full Text] [Related]
7. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
[TBL] [Abstract][Full Text] [Related]
8. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE
Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
[TBL] [Abstract][Full Text] [Related]
9. Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial.
Rascol O; Bronzova J; Hauser RA; Lang AE; Sampaio C; Theeuwes A; van de Witte SV
Parkinsonism Relat Disord; 2012 May; 18(4):370-6. PubMed ID: 22316635
[TBL] [Abstract][Full Text] [Related]
10. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
11. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H
Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088
[TBL] [Abstract][Full Text] [Related]
12. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
Pahwa R; Tanner CM; Hauser RA; Sethi K; Isaacson S; Truong D; Struck L; Ruby AE; McClure NL; Went GT; Stempien MJ
Mov Disord; 2015 May; 30(6):788-95. PubMed ID: 25650051
[TBL] [Abstract][Full Text] [Related]
13. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
Oertel W; Eggert K; Pahwa R; Tanner CM; Hauser RA; Trenkwalder C; Ehret R; Azulay JP; Isaacson S; Felt L; Stempien MJ
Mov Disord; 2017 Dec; 32(12):1701-1709. PubMed ID: 28833562
[TBL] [Abstract][Full Text] [Related]
14. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.
Metman LV; Del Dotto P; LePoole K; Konitsiotis S; Fang J; Chase TN
Arch Neurol; 1999 Nov; 56(11):1383-6. PubMed ID: 10555659
[TBL] [Abstract][Full Text] [Related]
15. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
[TBL] [Abstract][Full Text] [Related]
16. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
[TBL] [Abstract][Full Text] [Related]
17. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study.
Merello M; Nouzeilles MI; Cammarota A; Leiguarda R
Clin Neuropharmacol; 1999; 22(5):273-6. PubMed ID: 10516877
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
Ziegler M; Castro-Caldas A; Del Signore S; Rascol O
Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949
[TBL] [Abstract][Full Text] [Related]
19. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
Hauser RA; Shulman LM; Trugman JM; Roberts JW; Mori A; Ballerini R; Sussman NM;
Mov Disord; 2008 Nov; 23(15):2177-85. PubMed ID: 18831530
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease.
Luginger E; Wenning GK; Bösch S; Poewe W
Mov Disord; 2000 Sep; 15(5):873-8. PubMed ID: 11009193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
